(MedPage Today) — Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant chemotherapy, which caused a high rate of severe toxicity, according to a large randomized trial.
Overall survival…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/116983
Author :
Publish date : 2025-08-13 21:20:00
Copyright for syndicated content belongs to the linked Source.
